Epiomic Epidemiology Series: Schizophrenia Forecast in 27 Major Markets 2018–2028

March 2018 | 92 pages | ID: EC7FFE82DF2EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Forecast Report on Schizophrenia in 27 Major Markets

Schizophrenia is a mental illness characterised by psychosis, apathy and withdrawal, as well as cognitive impairment. It usually develops between late adolescence and young adult age and although no significant differences in the prevalence of schizophrenia have been observed between men and women overall, there are differences in age at onset and tendency to present certain symptoms. Schizophrenia constitutes a significant burden to social and professional life, with more severe forms also causing basic self-care problems. With its life-long duration, it is one of the leading causes of long-term disability worldwide.

This report provides the current prevalent population for schizophrenia across 27 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Finland, Denmark, Austria, Switzerland, Ireland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, the main comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of schizophrenia include:

• Diabetes mellitus
• Cardiopulmonary, metabolic, gastrointestinal and malignant diseases
• Abuse of psychoactive substances
• Sexually-transmitted diseases
• Psychosocial stress
• Adverse effects of antipsychotics

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Ability to quantify patient populations in global schizophrenia market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of schizophrenia and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding of the impact of specific co-morbid conditions on the prevalent population of schizophrenia patients.
• Identification of schizophrenia patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of schizophrenia patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR SCHIZOPHRENIA

COMORBIDITIES OF SCHIZOPHRENIA PATIENTS

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN SERVICES & SOLUTIONS

REPORTS & PUBLICATIONS

ONLINE EPIDEMIOLOGY DATABASES

ONLINE PHARMACEUTICAL PRICING DATABASE

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. The DSM-5 diagnostic criteria for schizophrenia
Table 2. Stages of the course of schizophrenia
Table 3. Prevalence of schizophrenia, total (000s)
Table 4. Prevalence of schizophrenia, males (000s)
Table 5. Prevalence of schizophrenia, females (000s)
Table 6. Schizophrenia patients with obesity, total (000s)
Table 7. Smoking patients with schizophrenia, total (000s)
Table 8. Schizophrenia patients with diabetes mellitus, total (000s)
Table 9. Schizophrenia patients with arterial hypertension, total (000s)
Table 10. Schizophrenia patients with dyslipidaemia, total (000s)
Table 11. Schizophrenia patients with COPD, total (000s)
Table 12. Schizophrenia patients with substance use disorder, total (000s)
Table 13. Schizophrenia patients with depression, total (000s)
Table 14. Schizophrenia patients with PTSD, total (000s)
Table 15. Schizophrenia patients with OCD, total (000s)
Table 16. Schizophrenia patients with generalized anxiety disorder, total (000s)
Table 17. Schizophrenia patients with panic disorder, total (000s)
Table 18. Schizophrenia patients with social phobia, total (000s)
Table 19. Abbreviations and acronyms used in the report
Table 20. USA prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 21. USA prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 22. Canada prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 23. Canada prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 24. France prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 25. France prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 26. Germany prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 27. Germany prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 28. Italy prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 29. Italy prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 30. Spain prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 31. Spain prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 32. UK prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 33. UK prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 34. Poland prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 35. Poland prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 36. Netherlands prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 37. Netherlands prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 38. Belgium prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 39. Belgium prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 40. Norway prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 41. Norway prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 42. Sweden prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 43. Sweden prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 44. Finland prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 45. Finland prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 46. Denmark prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 47. Denmark prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 48. Austria prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 49. Austria prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 50. Switzerland prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 51. Switzerland prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 52. Ireland prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 53. Ireland prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 54. Russia prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 55. Russia prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 56. Turkey prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 57. Turkey prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 58. Japan prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 59. Japan prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 60. China prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 61. China prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 62. South Korea prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 63. South Korea prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 64. India prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 65. India prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 66. Australia prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 67. Australia prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 68. Brazil prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 69. Brazil prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 70. Mexico prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 71. Mexico prevalence of schizophrenia by 5-yr age cohort, females (000s)
Table 72. Argentina prevalence of schizophrenia by 5-yr age cohort, males (000s)
Table 73. Argentina prevalence of schizophrenia by 5-yr age cohort, females (000s)